Tirzepatide and G21 topical therapy evaluated for cellulite in observational study

Cellulite is a highly prevalent condition associated with alterations in adipose tissue architecture, microcirculation, and connective tissue integrity. Emerging evidence suggests that cellulite may represent a manifestation of both local structural changes and systemic metabolic dysfunction. This study aimed to evaluate the independent and combined effects of systemic metabolic therapy with tirzepatide and a multi-target topical formulation (G21) on cellulite severity and body composition, addressing a gap in comprehensive treatment approaches.

This retrospective observational cohort study included 92 consecutively treated participants with grade II-III cellulite. Participants were categorized into three groups based on routine clinical practice: combination therapy (tirzepatide + G21), tirzepatide alone, or topical G21 alone. The primary outcome was the change in cellulite severity assessed using the Nürnberger-Müller classification scale over 12 months.

The provided abstract outlines the study's background, objectives, and methodology but does not present any specific results, statistical analyses, or quantitative findings. Therefore, no concrete data regarding the effects of tirzepatide or G21 on cellulite severity or body composition can be reported from this abstract.